WCN26-6028 Empagliflozin mediated metabolic reprogramming in VHL-wildtype ccRCC: metabolic insights and therapeutic opportunities

Read full text Summarise with VIRAT
Authors: Chaeyoung Lee, Taerin Kim, Hyuk Nam Kwon, Kyung Don Yoo
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Renal cell carcinoma (RCC) is a metabolically active malignancy characterized by dysregulated glucose utilization and mitochondrial dysfunction, suggesting that targeting metabolism could provide therapeutic benefits. Sodium–glucose cotransporter 2 (SGLT2) inhibitors, originally antidiabetic agents, have shown emerging anticancer potential by modulating oncogenic signaling and energy metabolism. However, the metabolic mechanisms underlying SGLT2 inhibition in renal cancer remain unclear. Given that metabolic dependencies in RCC vary with von Hippel–Lindau (VHL) mutation status, investigating SGLT2 inhibitor–induced alterations in VHL–wildtype cells may reveal context-specific vulnerabilities and therapeutic opportunities.

Fields of Study & Subjects

Cancer Hypoxia and Metabolism Renal cell carcinoma treatment Metabolism Diabetes and Cancer

Publication details

Journal / source
Kidney International Reports
Volume
11
Issue
4
Pages
104164–104164
Publication date
25 March 2026
Language
EN